Combination immunotherapy for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced bile duct cancer (including gallbladder cancer or intrahepatic/extrahepatic cholangiocarcinoma) that cannot be removed by surgery or has spread
- You have already tried chemotherapy and it didn't work
- Your tumor tests positive for a protein called EGFR
- You are able to care for yourself (ECOG 0-1)
- You have not received certain immunotherapies before (like PD-1/PD-L1 inhibitors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This study tests a new drug called becotatug vedotin, added to standard chemotherapy, for advanced bile duct cancer that has a specific protein called EGFR. The goal is to see if this combination helps shrink tumors or slow the cancer better than standard treatment alone.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests two immunotherapy drugs for people with advanced bile duct or gallbladder cancer that has EGFR protein and has not responded to earlier treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.